GYRE:NSD-Gyre Therapeutics Inc. (USD)

COMMON STOCK | Others |

Last Closing

USD 13.86

Change

-1.74 (-11.15)%

Market Cap

USD 1.50B

Volume

0.13M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

+2.85 (+1.55%)

USD 23.82B
ACWI iShares MSCI ACWI ETF

+1.27 (+1.15%)

USD 18.41B
IBIT iShares Bitcoin Trust

+2.60 (+7.41%)

USD 17.74B
CGABL The Carlyle Group Inc. 4.625% ..

+0.34 (+1.88%)

USD 16.14B
JEPQ JPMorgan Nasdaq Equity Premium..

+0.41 (+0.76%)

USD 13.03B
TBIL Rbb Fund Inc - Us Treasury 3 M..

N/A

USD 3.07B
IBTE iShares iBonds Dec 2024 Term T..

N/A

USD 2.82B
IBTF iShares iBonds Dec 2025 Term T..

+0.02 (+0.06%)

USD 2.27B
NVDL GraniteShares 1.5x Long NVDA D..

+2.87 (+7.13%)

USD 2.05B
USCL iShares Climate Conscious & Tr..

+0.74 (+1.19%)

USD 2.01B

ETFs Containing GYRE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.05% 7% C- 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.05% 7% C- 10% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.50B 95% A 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector